Efficacy of Empagliflozin on Acute Coronary Syndrome with Type 2 Diabetes: Open-label Randomized Controlled Trial
- Conditions
- Acute Coronary Syndrome with Type 2 Diabetes
- Registration Number
- JPRN-UMIN000020951
- Lead Sponsor
- The Sakakibara Heart Institute of Okayama
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Not provided
1) Patients with hypersensitivity to the components of Empagliflozin 2) Patients with severe ketosis, diabetic coma or pre-coma 3) Patients with severe infection, before and after surgery, severe trauma 4) Patients with dehydration 5) Patients with uncontrolled hypertension (sBP>180mmHg under medication) or low blood pressure (sBP<85mmHg) 6) Patients with advanced renal dysfunction or patients on dialysis (eGFR<30) 7) Patients with severe hepatic dysfunction 8) Patients with congenital heart disease or valvular disease 9) Patients with severe complications such as malignant neoplasm and severe infections 10) Patients with a history of heart transplant 11) Patients with drug or alcohol dependence 12) Patients with urinary tract or genital infection 13) Patients with pregnancy, or possibility and hope 14) Patients who have participated in clinical studies using other investigational or unapproved medicines within 3 months 15) Patients whom physician in charge considered inappropriate for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method